A Clinical Observation of Intravenous Urapidil Versus Nitroglycerin in the Treatment of Advanced Heart Failure

Objective The aim of this study was to evaluate the Short-term efficacy of urapidil for the treatment of patients with advanced heart failure. Methods A total of 48 patients with advanced heart failure(NYHA class Ⅳ)were randomly assigned to open-labeled treatment with urapidil(n=24)or nitroglycerin (n=24 ) . Both groups were comparable in respect of age, heart rate and blood pressure. Intravenous urapidil(50～100μg/min)or nitroglycerin(10～20μg/min)was administered for 24 hours(based on blood pressure) in addition to ordinarily treatment (diuretic and digitalis).Heart rate, blood pressure were measured and echocardiography was performed before and after the treatment. Results No significant changes of heart rate, diastolic blood pressures were found between two groups. In the nitroglycerin group, only ejection fraction(P0.05)increased significantly and E doc prolonged(P0.05).In the urapidil group, the systolic stroke volume measured by echocardiography increased(P0.05)significantly compared to the baseline, and so were ejection fraction(P0.05)and AoVmax(P0.05).Conclusions Short term use of intravenous urapidil for advanced heart failure significantly improve cardiac systolic function, especially in the patients with hypertension. Also, it is safe and well tolerated.